Who is the CEO of Mekics?

According to the DART company overview, Mekics' representative director is 김종철 (name as registered in Korean). The company was founded on 1998-11-26.

Where is Mekics listed?

Mekics trades on the Korea Exchange KOSDAQ market under the ticker 058110. Its fiscal year ends in December.

Does Mekics pay a dividend?

Mekics did not pay a cash dividend for fiscal 2025, according to its annual report.

Does Mekics have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); Turnaround (latest quarter swung to an operating profit from a loss a year earlier); Insider buying (officers or major shareholders reported adding shares (30 days)). 3 more signals are shown on the page. These are factual flags, not investment advice.

Which companies are in the same industry as Mekics?

Under the Korean Standard Industrial Classification recorded on DART, Mekics is grouped with 72 other listed companies in medical devices. The most covered in Korean news over the past 30 days are CG MedTech, Seers and Sky Labs.

Mekics KRX:058110KOSDAQ

멕아이씨에스 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days0

DART filings, 7 days1

Articles tracked5since Sep 11

In Q2 2026, Mekics reported revenue of ₩3.9bn, up 63.3% year on year, and operating profit of ₩178m. Mekics (멕아이씨에스) appeared in 0 Korean news articles and 1 DART filing over the past seven days.

Filing signals Turnaround Insider buying New 5% holder Major holder adding Private placement Dilution risk Share pledge Screener

Mekics quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩3.9bn	+63.3%	₩178m margin 4.6%	₩245m
Q1 2026	₩3.9bn	+33.4%	₩366m margin 9.4%	₩677m
Q4 2025 derived	₩3.2bn	-11.2%	₩263m margin 8.2%	₩336m
Q3 2025	₩2.8bn	+68.7%	−₩298m margin −10.7%	−₩180m
Q2 2025	₩2.4bn	-25.2%	−₩1.7bn margin −71.4%	−₩1.7bn
Q1 2025	₩2.9bn	-0.3%	−₩1.1bn margin −36.6%	−₩1.1bn
Q4 2024 derived	₩3.6bn	+0.8%	−₩4.2bn margin −114.9%	−₩4.3bn
Q3 2024	₩1.7bn	-54.3%	−₩2.4bn margin −142.9%	−₩2.4bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Mekics top stories 2 weeks, by number of outlets

No story covered by multiple outlets in the past two weeks.

Latest Mekics news Korean headlines

Oct 813:44

멕아이씨에스, 자사주 37.5만주 소각
리드경제
Oct 807:37

[오늘의 IR] 스피어ㆍ멕아이씨에스ㆍ제이에스링크 등
이투데이JS Link Sphere
Sep 1508:16

멕아이씨에스, 차세대 하이브리드 인공호흡기 'MV50' 유럽 CE MDR 획득
아시아경제
Sep 1417:44
멕아이씨에스, 9억9천만원 유상증자…에스지헬스케어에 제3자배정
연합뉴스경제Sghealthcare
1 more on this story · 1 outlets
- 멕아이씨에스, 9억9000만원 유상증자…에스지헬스케어에 제3자배정아시아경제 · Sep 14 17:48

Articles per day 2 weeks

Company profile

CEO: 김종철
Industry: Medical devices
Founded: 1998-11-26
Fiscal year-end: December
Head office: 경기도 파주시
Website: mek-ics.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

김종철24.35%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Medical devices

All in industry

Company	Latest quarter op. profit	Articles 30d
CG MedTech	₩333m	82
Seers	₩12.9bn	77
Sky Labs	–	71
Medyssey	–	47
Classys	₩43.9bn	43
Won Tech	₩11.1bn	42
Dio	₩4.4bn	36
InBody	₩17.7bn	29

Compare Mekics side by side with these companies

Mekics DART filings

11:11

Other 임시주주총회결과
Other
Oct 2209:19

Insider ownership report 임원ㆍ주요주주특정증권등소유상황보고서
Ownership reports
Oct 2114:29

5% ownership report [기재정정]주식등의대량보유상황보고서(일반)
Ownership reports
Oct 2113:21

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Oct 2112:59

5% ownership report [기재정정]주식등의대량보유상황보고서(일반)
Ownership reports
Oct 1510:55

Other [기재정정]주주총회소집공고
Other
Oct 1510:23

Other [기재정정]의결권대리행사권유참고서류
Other
Oct 1417:02

Other 의결권대리행사권유참고서류
Other
Oct 1416:36

Other [기재정정]주주총회소집결의 (임시주주총회)
Other
Oct 1416:29

Other 주주총회소집공고
Other
Oct 613:36

Investor relations event 기업설명회(IR)개최
Other
Oct 613:35

Investor relations event 기업설명회(IR)개최
Other

Mentioned alongside 2 weeks

No co-mentioned companies yet.

Mekics FAQ

Who is the CEO of Mekics?: According to the DART company overview, Mekics' representative director is 김종철 (name as registered in Korean). The company was founded on 1998-11-26.
Where is Mekics listed?: Mekics trades on the Korea Exchange KOSDAQ market under the ticker 058110. Its fiscal year ends in December.
What were Mekics' latest quarterly results?: In Q2 2026, Mekics reported revenue of ₩3.9bn, up 63.3% year on year, and operating profit of ₩178m. Figures come from reports filed on DART.
Does Mekics pay a dividend?: Mekics did not pay a cash dividend for fiscal 2025, according to its annual report.
Does Mekics have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); Turnaround (latest quarter swung to an operating profit from a loss a year earlier); Insider buying (officers or major shareholders reported adding shares (30 days)). 3 more signals are shown on the page. These are factual flags, not investment advice.
Which companies are in the same industry as Mekics?: Under the Korean Standard Industrial Classification recorded on DART, Mekics is grouped with 72 other listed companies in medical devices. The most covered in Korean news over the past 30 days are CG MedTech, Seers and Sky Labs.